EDIT · ISSUER CIK 1650664
Editas Medicine, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 Editas Medicine, Inc. insiders reported $0.00 of open-market purchases and $21K of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 4 of 4 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$21KInsider selling
−$21KNet open-market
Sep 4, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 202616:27 | Sep 3, 2026 | EDIT | EVP, CHIEF SCIENTIFIC OFFICER | S · Sell10b5-1 | $3.04 | −709 | 61,660 | -1% | −$2K | ||
| Sep 4, 202616:25 | Sep 3, 2026 | EDIT | SVP, Chief Financial Officer | S · Sell10b5-1 | $3.04 | −453 | 13,839 | -3% | −$1K | ||
| Sep 4, 202616:22 | Sep 3, 2026 | EDIT | CEO, Director | S · Sell10b5-1 | $3.04 | −5,124 | 243,189 | -2% | −$16K | ||
| Aug 5, 202616:07 | Aug 3, 2026 | EDIT | SVP, Chief Financial Officer | S · Sell10b5-1 | $2.58 | −678 | 14,292 | -5% | −$2K |